Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease: Systematic review: polycystic ovary syndrome, NAFLD and bariatric surgery
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common disorder for women of child-bearing age and is associated with metabolic syndrome (MS). AIM: To assess the literature for associations between polycystic ovary syndrome and non-alcoholic fatty liver disease (NAFLD). METHODS: We performed a systematic review using PubMed-search for peer-reviewed articles related to polycystic ovary syndrome and NAFLD. Articles were summarised and grouped according to different sections defining interactions of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease as well as risk factors, pathogenic pathways and treatment options. RESULTS: Obesity is a common factor involved in both polycystic ovary syndrome and non-alcoholic fatty liver disease. Obesity causes non-alcoholic fatty liver disease and aggravates hirsutism and menstrual disorders in polycystic ovary syndrome. Insulin resistance, a hallmark of metabolic syndrome is observed in 50-80% of women with polycystic ovary syndrome and patients with non-alcoholic fatty liver disease. Recent findings suggest that women with polycystic ovary syndrome may be at risk for developing non-alcoholic fatty liver disease and conversely, non-alcoholic fatty liver disease may be a risk for polycystic ovary syndrome. Based on the association of polycystic ovary syndrome and other metabolic abnormalities, such as insulin resistance, hyperandrogenism, obesity and non-alcoholic fatty liver disease, the candidate genes have been speculated for polycystic ovary syndrome. Closer scrutiny of these genes placed most of their proteins at the crossroads of three highly inter-related conditions: metabolic syndrome, obesity and non-alcoholic fatty liver disease. In most studies, the prevalence of both polycystic ovary syndrome and non-alcoholic fatty liver disease rises proportionally to the degree of insulin resistance and increases in the mass of adipose tissue. CONCLUSIONS: Non-alcoholic fatty liver disease is considered as the hepatic manifestation of metabolic syndrome. Similarly, it seems appropriate to consider polycystic ovary syndrome as the ovarian manifestation of metabolic syndrome. Both these conditions can co-exist and may respond to similar therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 3×
“follicles cannot mature and give rise to the cysts seen in patients with PCOS.(1)”
InfluentialRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759
Low grade chronic inflammation in women with polycystic ovarian syndrome
Kelly, C. C. J., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. C., & Sattar, N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7580 · Cited by 640
Impact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 1×
“The relevance of FTO to PCOS is suggested by the high prevalence of obesity in PCOS, about 60% to 70%.(70) The function of FTO was not known until recently, when a transcriptional coactivator activity of FTO was demonstrated for both unmethylated and methylation-inhibited CCAAT ⁄ enhancer binding proteins (C ⁄ EBPs)-d…”
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
Role of the GATA Family of Transcription Factors in Endocrine Development, Function, and Disease
Viger, R. S., Guittot, S. M., Anttonen, M., Wilson, D. B., & Heikinheimo, M. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0513 · Cited by 270 · cited 1×
“2, a critical islet transcription factor.(49) Interestingly, CYP11A is suppressed in response to fenofibrate, a hypolipidemic ligand for PPARa used in the treatment of hypertriglyceridemia and combined hyperlipidemia, being partic-”
McLaughlin, T., Allison, G., Abbasi, F., Lamendola, C., & Reaven, G. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.032 · Cited by 268 · cited 1×
“resistance and obesity, these conditions, to some degree, remain independent from each other.(35) Some obese patients are insulin sensitive and there are lean patients who have substantial resistance to insulin.”
5 α-reductase activity in polycystic ovary syndrome
Stewart, P. M., Edwards, C. R. W., Shackleton, C. H. L., & Beastall, G. H. (1990) · The Lancet · doi:10.1016/0140-6736(90)90664-q · Cited by 189
The impact of bariatric surgery on menstrual patterns
Teitelman, M., Grotegut, C., Williams, N., & Lewis, J. (2006) · Obesity Surgery · doi:10.1381/096089206778870148 · Cited by 179
Evidence of proatherogenic inflammation in polycystic ovary syndrome
González, F., Rote, N. S., Minium, J., & Kirwan, J. P. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.022 · Cited by 135 · cited 1×
“lean women with PCOS maintain normal sensitivity to insulin, adiponectin biosynthesis deficiency(11) or chronic low level inflammation is often present.(12)”
Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
Weiner, R. A. (2010) · Digestive Diseases · doi:10.1159/000282102 · Cited by 113
Increased 5α-Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome
Vassiliadi, D. A., Barber, T. M., Hughes, B. A., McCarthy, M. I., Wass, J. A. H., Franks, S., Nightingale, P., Tomlinson, J. W., Arlt, W., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0837 · Cited by 110 · cited 1×
“In particular, SRD5A activity correlated with BMI, insulin levels and HOMA scores.(59) The activity of 5-aalpha reductase is sensitive to the antidiabetic drug pioglitazone(60) and to weight loss.”
Tomlinson, J. W., Finney, J., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0094 · Cited by 91
Allemand, M. C., Irving, B. A., Asmann, Y. W., Klaus, K. A., Tatpati, L., Coddington, C. C., & Nair, K. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004274 · Cited by 65 · cited 2×
“One suggested mechanism linking IRS-1 and PCOS involves an co-stimulatory interaction between testosterone and insulin that promotes the serine phosphorylation of IRS-1 Ser(636 ⁄ 639), that, in turn, influence the phosphorylation of its downstream targets, particularly, Akt, mTOR and S6K.(105)”
Jensterle, M., Janez, A., Mlinar, B., Marc, J., Prezelj, J., & Pfeifer, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0857 · Cited by 47 · cited 1×
“In particular, GLUT4 levels are reduced both in endometrial tissue(13) and in adipose.(114) It is well known that insulin resistance”
Mohamed-Hussein, Z.-A., & Harun, S. (2009) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-6-18 · Cited by 46
Cited by
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Self-citationDumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1050-7 · Cited by 327
The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View
Lindenmeyer, C. C., & McCullough, A. J. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.003 · Cited by 271
Metadata
- Authors
- Baranova, A., Tran, T. P., Birerdinc, A., & Younossi, Z. M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-01-20
- Volume
- 33
- Issue
- 7
- Pages
- 801-814
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W2170046777
- Cited by
- 146
- References
- 19
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.